Pharmaceutical Firm, ARTEC, Inc., Reports Moving on in the Development of an Improved Tubercin
and the Testing of HIV/AIDS Human Patients in Africa
May 27 2010 - OKLAHOMA CITY - ARTEC, Inc., (Pink Sheets: ATKJ), has improved Tubercin T-5 an immunostimulant. In the last two years,
Artec asserts that TubercinT has improved significantly and tested in Africa, in the company's opinion, with positive results on human patients afflicted
with HIV/AIDS. Under strict confidential conditions, the results received were most encouraging. Artec is engaged in full pursuit of obtaining FDA
registration of TubercinT in Africa.
With ample funding, the success of Artec is within reach. The steady support of Artec's shareholders and associates has fostered its
accomplishments. Artec thanks all the aforementioned for their loyalty and support.
Artec Inc. is a small entrepreneurial pharmaceutical company in a very competitive field of "Discovering Medicine" to curb HIV/AIDS
and cancer. The costs involved are very steep and the challenges bordering on insurmountable. Artec has succeeded in coming this far where, in the company's
opinion, significant research for many years and billions of dollars spent have not. Artec thanks its partner Dr. Tai Ho Chung, his son C.C. Chung and
Kyungpook National University (Seoul, Korea) for the patented baseline research prototype, TubercinT. T-5. Artec looks forward to working together
with Dr. Chung and C.C. Chung to bring this improved Tubercin to the world. Artec's Leading Scientist, Dr. J.K. Park and his associates have
also helped, in the company's view, improve the efficacy of the new Tubercin. Artec also thanks Dr. J.K. Park and everyone working under
his leadership and in unison with his association with them.
Artec is serious about the future. The firm has recently explored such issues as Permanent Headquarters; High Volume Manufacturing of
Tubercin; and Developing a Vaccine for Prevention of HIV/AIDS yet Impacting HIV/AIDS and cancer. Artec's progress in the next few months is considered critical
for continued successes.
Artec is resolved to bring Tubercin to the market in the near future. Artec appreciates the continued support. The company will disclose more appropriate and
specific information in the future. The confidential agreements do not afford Artec the liberty to disclose specific information at this time.
The Company cautions the investors that forward-looking statements in this press release involve risks and uncertainties pursuant to the "Safe Harbor" provisions
of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to
publicity update these forward-looking statements to reflect the Company's expectation with regard to these forward-looking statements to reflect the
Company's expectation with regard to these forward-looking statements or the occurrence of unanticipated events.
Dr. Ronald Shinn, President,
Reproduced with permission - "ARTEC, Inc."